🚀 New in Radiotherapy & Oncology: An adaptable cost-analysis framework for radiotherapy, applied to proton vs. photon therapy for lung cancer. Findings show protons remain costlier, but efficiency gains could reduce disparities📖 Read more: thegreenjournal.com/article/S0167-… #PBT #photons

PSMA PET after radiotherapy: Timing matters! ⏳ In 217 lesions, uptake declined over time, lowest at 9–12 months. Prostate lesions showed prolonged uptake vs. lymph nodes/bone. Beware of pseudo-progression on early scans! 📉 Full study: sciencedirect.com/science/articl…

Investigator-initiated study sponsored by Institut Jules Bordet Instituut and chaired by Alex De Caluwe and Laurence Buisseret. Primary endpoint results presented at #ESMO24 oncologypro.esmo.org/meeting-resour…

📢 New ESTRO-EANO guideline in The Green Journal! Recommendations for radiotherapy in IDH-mutant WHO grade 2 & 3 diffuse gliomas: ✅ Target volume delineation ✅ Imaging & planning techniques ✅ Dose & fractionation A must-read for neuro-oncology teams! thegreenjournal.com/article/S0167-…

🚨 Call for Papers! The 4 ESTRO journals are uniting for a landmark issue on reirradiation—a cutting-edge approach offering new hope to patients with recurrent cancers. Submit your research & help shape the future of cancer care! 🔗 thegreenjournal.com/content/Reirra… #Reirradiation #RadOnc

🚨 New study in The Green Journal: Salvage #radiotherapy with VMAT shows promising outcomes for recurrent #ProstateCancer after #HIFU. ✅ Low toxicity ✅ No recurrences during follow-up ✅ A potential standard of care? thegreenjournal.com/article/S0167-… #Oncology

🌍 Society Matters — a new section in the Green Journal! Exploring how radiation oncology intersects with climate, equity, policy & more. 📖 Read the first editorial: sciencedirect.com/science/articl… 💬 What should we cover next? #RadiationOncology #SocietyMatters #ESTRO #Sustainability

🤖 New in the Green Journal: Most radiation oncology patients support AI/ML in their care — but they want transparency, human connection, and equity. 📄 Read the study: sciencedirect.com/science/articl… #RadiationOncology #AIinHealthcare #GreenJournal #SocietyMatters #ESTRO

Pleased to share our latest work in Radiotherapy & Oncology In-field lung re-SABR achieves excellent outcomes with low toxicities. Size, dose, timing matters. Best results seen in recurrent tumours <2cm, cumulative BED ≥200 Gy, and interval >12 months. thegreenjournal.com/article/S0167-…

🔥 Can SABR work twice? Meta-analysis shows in-field #SABR reirradiation offers 78% 1-year control with low toxicity—especially for small tumours, high BED (≥200 Gy), & long intervals. 💡 A safe, effective salvage option for recurrent #NSCLC. 📖 thegreenjournal.com/article/S0167-… #radonc

Stereotactic reirradiation for in-field lung cancer recurrence after stereotactic ablative radiotherapy - Kevin Jang (Kevin Jang) Radiotherapy & Oncology oncodaily.com/science/kevin-… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #SABR #LungCancer

🧠 New review sheds light on how to select and delineate post-op radiotherapy target volumes in oral cavity SCC. A must-read for H&N specialists 🔗thegreenjournal.com/article/S0167-… #RadOnc #HeadandNeckCancer #OralCancer #Radiotherapy

📢 Just 1 week to go until #ESTRO2025! The abstract book is live — have you found yours? 👉 user-swndwmf.cld.bz/ESTRO-2025-Abs… From AI to adaptive RT, this year’s programme is packed with innovation. What sessions are you most excited for? #RadiationOncology #ESTROabstracts

🔬 New in The Green Journal: RTQA matters. This first meta-analysis links radiotherapy protocol deviations to worse survival in cancer trials. OS HR=1.65, PFS HR=1.79. Real-time QA could improve outcomes sciencedirect.com/science/articl… #RTQA #Oncology #RadOnc

👏 A heartfelt thank you to our top reviewers over the past year at Radiotherapy & Oncology (The Green Journal)! Your expertise, time, and dedication help uphold the highest standards in our field. We deeply appreciate your contributions. #PeerReview #GreenJournal

📢 Don’t miss the Green Journal–Lancet Oncology joint plenary at #ESTRO2025! 🗓 Sun May 4 | ⏰ 11:40–12:45 📍 Plenary Hall Top clinical trials in GI & SBRT from 🇬🇧 🇳🇱 🇨🇳 — including PLATO ACT 4, STAR-TREC, PRIME-RT & more. #Radiotherapy #Oncology #GreenJournal

We are really looking forward to this session! Can't wait to see you all there!

We’re no longer posting here. Join us on LinkedIn for the latest updates! 📢 Catch our Editor-in-Chief Pierre Blanchard in a new interview on: ✨ The evolving role of journals 🤝 Cross-journal collaboration 🌱 Tips for early-career researchers 🔗 linkedin.com/feed/update/ur…

🚀 Thrilled to announce 3 new clinical trials in Radiotherapy & Oncology in partnership with The Lancet Oncology Lancet Oncology): ✨ ESO-SPARE 🔍 DBCG IMN2 post-hoc 📊 FAST-Forward nodal sub-study More details coming soon! 👀 #ESTRO2025 #GreenJournal

We’re moving our updates and conversations from Twitter X to LinkedIn! 🚀Follow us at TipsRO LinkedIn page linkedin.com/showcase/tipsr… to stay connected with the latest in technical innovations and patient support in radiation oncology. See you there! ESTRO Radiotherapy & Oncology